The Medical Letter on Drugs and Therapeutics
Rosiglitazone (Avandia) Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The cardiovascular safety of the thiazolidinedione rosiglitazone (Avandia – GlaxoSmithKline) is in the news again, with some authorities calling for its removal from the market (New York Times, February 19, 2010).

THIAZOLIDINEDIONES — The thiazolidinediones rosiglitazone and pioglitazone (Actos) are insulin sensitizing agents used to treat hyperglycemia in patients with type 2 diabetes. They are often used as a second or third agent with metformin (Glucophage, and others) and/or a sulfonylurea such as glimepiride (Amaryl, and others).1 Both rosiglitazone and pioglitazone can cause edema and weight gain and increase the risk of congestive heart failure.

AN OPEN-LABEL RANDOMIZED TRIAL — Among 4447 previously treated patients randomly assigned either to rosiglitazone added as a second drug to metformin or a sulfonylurea, or to metformin plus ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Rosiglitazone (Avandia) Revisited
Article code: 1333a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian